Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters

Reuters

2025/06/12

Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters

Teleflex Inc. $(TFX)$, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542451871"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542451871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542451871?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542451871","market":"nz","top_or_hot":-1,"title":"Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teleflex Inc. <a href=\"https://laohu8.com/S/TFX\">$(TFX)$</a>, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-12 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teleflex Inc. <a href=\"https://laohu8.com/S/TFX\">$(TFX)$</a>, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL8HjHww:1","article_id":"2542451871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542451871","pubTimestamp":1749724213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow Chlorhexidine-Impregnated Central Venous Catheters. Teleflex Inc. , a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow Chlorhexidine-Impregnated Central Venous Catheters . The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections  in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue and Arrowg+ard Blue Plus CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","TFX":"泰利福"},"translate_title":"Teleflex Inc.宣布新研究表明Arrow™氯己定浸渍中心静脉导管的感染率降低70.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TFX":0.9},"content_text":"Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n    \n\n        Teleflex Inc. $(TFX)$, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}